Details for Patent: 8,163,306

✉ Email this page to a colleague

Which drugs does patent 8,163,306 protect, and when does it expire?

Patent 8,163,306 protects ELEPSIA XR and is included in one NDA.

This patent has twenty-two patent family members in eighteen countries.

Summary for Patent: 8,163,306

Patent landscape, scope, and claims:

Title:	Oral drug delivery system
Abstract:	An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
Inventor(s):	Dharmadhikari; Nitin Bhalachandra (Mumbai, IN), Zala; Yashoraj Rupsinh (Mumbai, IN), Singh; Amarjit (Mumbai, IN)
Assignee:	Sun Pharma Advanced Research Company (Andheri (E), Mumbai, IN)
Application Number:	10/572,502
Patent Claim Types: see list of patent claims	Composition; Delivery; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,163,306

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-001	Dec 20, 2018		DISCN	Yes	No	8,163,306	⤷ Subscribe	Y				⤷ Subscribe
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-002	Dec 20, 2018		DISCN	Yes	No	8,163,306	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,163,306

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
India	987/MUM/2003	Sep 19, 2003

PCT Information
PCT Filed	June 30, 2004	PCT Application Number:	PCT/IN2004/000192
PCT Publication Date:	May 06, 2005	PCT Publication Number:	WO2005/039481

International Family Members for US Patent 8,163,306

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	200603602	⤷ Subscribe
Austria	551051	⤷ Subscribe
Australia	2004283565	⤷ Subscribe
Australia	2011200881	⤷ Subscribe
Brazil	PI0414305	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.